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Abstract
Apocrine carcinoma of the breast is a distinctive malignancy with unique morphological and molecular features, generally
characterized by being negative for estrogen and progesterone receptors, and thus not electable for endocrine therapy.
Despite the fact that they are morphologically distinct from other breast lesions, no standard molecular criteria are currently
available for their diagnosis. Using gel-based proteomics in combination with mass spectrometry and immunohistochem-
istry we have identified two novel markers, HMGCS2 and FABP7 that categorize the entire breast apocrine differentiation
spectrum from benign metaplasia and cysts to invasive stages. Expression of HMGCS2 and FABP7 is strongly associated with
apocrine differentiation; their expression is retained by most invasive apocrine carcinomas (IAC) showing positive
immunoreactivity in 100% and 78% of apocrine carcinomas, respectively, as compared to non-apocrine tumors (16.7% and
6.8%). The nuclear localization of FABP7 in tumor cells was shown to be associated with more aggressive stages of apocrine
carcinomas. In addition, when added to the panel of apocrine biomarkers previously reported by our group: 15-PGDH,
HMGCR and ACSM1, together they provide a signature that may represent a golden molecular standard for defining the
apocrine phenotype in the breast. Moreover, we show that combining HMGCS2 to the steroidal profile (HMGCS2+/
Androgen Receptor (AR)+/Estrogen Receptor(ER)-/Progesteron Receptor (PR)- identifies IACs with a greater sensitivity (79%)
as compared with the steroidal profile (AR+/ER-/PR-) alone (54%). We have also presented a detailed immunohistochemical
analysis of breast apocrine lesions with a panel of antibodies against proteins which correspond to 10 genes selected from
published transcriptomic signatures that currently characterize molecular apocrine subtype and shown that except for
melanophilin that is overexpressed in benign apocrine lesions, these proteins were not specific for morphological apocrine
differentiation in breast.
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Introduction
Apocrine carcinoma of the breast exhibits the same histological
growth pattern as invasive ductal carcinoma of no special type,
and is currently diagnosed on basis of the presence of characteristic
apocrine-type epithelial cell morphology observed in more than
90% of tumor cell mass. These tumors represent a relatively rare
subtype, constituting less than 5% of all breast cancers [1,2].
Recently, Dellapasqua and coauthors reported a frequency of
apocrine carcinoma of 0.8% after analyzing a cohort of 6971
breast cancer patients [3]. This high discrepancy is most likely
because there is no consensus on standardized reproducible
diagnostic criteria as the current WHO classification of breast
malignancies provides an imprecise definition of apocrine carci-
noma of the breast [4], a fact that has produced controversial and
heterogeneous conclusions in the scientific literature in terms of a
precise immunohistochemical profile and molecular classification
of invasive apocrine carcinomas (IACs) [1,5,6,7,8,9]. Moreover,
apocrine differentiation is detected in several other breast tumor
subtypes including papillary, micropapillary, tubular, and lobular
carcinoma [9]. In addition to characteristic morphological features
IACs are generally accepted to have a distinct hormonal profile,
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being estrogen receptor (ER) and progesterone receptor (PR)
negative, but androgen receptor (AR) positive [10]. Again, it
should be noted that throughout the years IACs have been
reported as ER positive in 3.8–60% of cases, PR positive in 4.8%–
40% and AR positive in 56%–100% [1], underscoring the
variability in observation reported for these tumors. There are
not much data regarding the clinical outcome of those tumors and
the results are not compelling enough partly because of limited
numbers of samples selected for the analysis [9]. A comprehensive
study published recently has revealed a significantly worse disease
free survival for pure IACs as compared with invasive ductal
carcinoma (IDC) [3].
A few years ago several transcriptomic studies were performed
with the aim to classify these types of breast malignancy at the
molecular level. In the gene profiling study carried out by Perou
and coauthors, IACs clustered within the basal-like subtype of
breast carcinomas [11]. Thereafter, Farmer and colleagues [12]
identified a subset of breast tumors characterized by increased
androgen signaling and a distinctive expression profile, which they
called ‘‘molecular apocrine’’ as these lesions did not exhibit all the
histopathological traits that are characteristic of classical apocrine
carcinomas. Molecularly defined apocrine carcinomas include
tumors that share some common expression characteristics with
the HER2+ group (ER-/PR-/HER2+) in the Stanford classifica-
tion as well as with some lesions that exhibit features of the basal-
like/triple negative group (high grade lesions; ER-/PR-/HER2-).
It was also shown that it is possible with microarray data to divide
mammary tumors into 3 major groups based on steroid hormone
status: luminal (ER+/AR+), basal (ER2/AR2), and molecular
apocrine (ER2/AR+) with a certain association between apocrine
histology and molecular apocrine type [13]. Finally, a meta-
analysis study performed by Sanga and colleagues [14] showed
that the subgroups described by Farmer and Doane are highly
similar and both predict the molecular apocrine subset in other
cohorts. To date, however, the relationship between molecular
apocrine breast carcinoma and histopathologically defined apo-
crine tumors remains questionable [15].
With the aim to develop molecular criteria to reproducibly
categorize IACs at the protein level we have undertaken a
systematic proteomic analysis of well-defined set of apocrine
carcinomas aimed at identifying biomarkers that may characterize
and subtype these lesions to a greater detail, and to search for
targets that may lead to the development of novel targeted
therapies and chemoprevention strategies [2,16,17,18,19]. Ac-
cordingly, we have identified a number of apocrine protein
markers that include 15-prostaglandin dehydrogenase (15-PGDH)
and acyl-CoA synthetase medium-chain family member 1
(ACSM1) which together with a set of categorizing markers that
are predominantly expressed (AR, CD24) or not expressed (bcl-2,
GATA-3) by apocrine metaplastic lesions in benign breast lesions,
were proven to be specific for both apocrine ductal carcinoma in
situ (ADCIS) and IAC [2,16,17,19,20]. This apocrine signature
has been shown to identify unambiguously 13 out of 14 ADCIS
(92.9%) and 20 out of 33 (60.6%) IACs in a well characterized set
of apocrine carcinomas [2] in which more than 90% of the tumor
cells exhibited cytological features typical of apocrine cells [21].
Here we describe two additional markers, brain fatty acid binding
protein (FABP7) and hydroxymethylglutaryl (HMG)-CoA synthase
2 (HMGCS2), which in combination with markers in the protein
signature described previously [19] allowed to identify ADCISs
and IACs that failed to be detected in previous studies. Moreover,
our results demonstrate that HMGCS2 added to the steroid
hormone receptor signature (ER-/PR-/AR+) identifies apocrine
tumors from other breast cancer subtypes with greater sensitivity
as compared to steroid receptor profile alone. We have also
presented a detailed immunohistochemistry (IHC) analysis of a set
of proteins corresponding to 10 genes selected from transcriptomic
signatures that currently characterize molecular apocrine subtype
[12,13,14,22] to evaluate the complementarity of these two
approaches.
Results
Determination of the specificity of FABP7 and HMGCS2
antibodies
The sensitivity and specificity of antibodies are critical
parameters in the design and development of reliable IHC-based
assays for analysis and validation of potential biomarkers. To
determine if FABP7 and HMGCS2 antibodies are specific enough
in terms of IHC staining to identify benign and malignant
apocrine lesions [2,16] we used a three-pronged strategy
developed in our laboratory and described in detail elsewhere
[23]: (i) analysis of potential cross-reactivity by 2D Western
blotting (2D-WB), (ii) mass spectrometry validation of correspond-
ing silver-stained protein spots superimposed with 2D-WB and (iii)
IHC experiments with blocking of antibodies with a corresponding
protein/epitope. This approach combines the intrinsic sensitivity
and cellular resolution of IHC, with the specificity of 2D-WB and
MS-based identification, and the overall protein analysis capability
of gel-based proteomics [24].
In previous studies we demonstrated overexpression of FABP7
and HMGCS2 by apocrine cells as compared to their normal
breast epithelial cell counterparts [2]. 2D-PAGE/MS/2D-WB
analyses were performed on tissue lysates obtained from six
patients and the results for one matched apocrine cyst/normal
epithelia pair are illustrated in Figure 1. As shown, the anti-
HMGCS2 antibody detected several train-line protein spots of
similar Mw (about 57 kDa) (Figure 1A and C) compatible with
multiple post-translational modifications of the protein [25,26].
The identity of these spots as HMGCS2 was confirmed by MS
analysis (data not shown). The antibody recognizing FABP7
detected a single spot with Mw >15 kDa (Figure 1A and D). No
protein spots matched to the positions of FABP7 and HMGCS2
were detected on the 2D gel of normal breast tissue (Figure 1B).
The results show that HMGCS2 and FABP7 are recognized by
their corresponding antibodies, and, most importantly, cross-
reactivity was detected for neither HMGCS2 nor FABP7 with any
of the thousands of proteins resolved by 2D PAGE, demonstrating
a high specificity for these antibodies. In addition, to exclude the
possibility that anti-FABP7 may react with some close homologues
from the FABP protein family [27], we performed 2D–WB with
protein extracts from several triple-negative breast cancer samples
in which we had previously observed aberrant expression of three
other FABP protein family members, namely, FABP3, FABP4 and
FABP5 [23]. As seen in Figure S1, anti-FABP7 specifically
recognized only a single spot corresponding to FABP7 and no
cross reactivity was detected with FABP3, FABP4 or FABP5. The
identities of all protein spots were determined by mass spectrom-
etry analysis (data not shown). The high specificity of both
antibodies was further confirmed by IHC experiments with
blocking of antibodies with a corresponding full length recombi-
nant protein (data not shown). Based on these results it can be
concluded that the antibodies against FABP7 and HMGCS2
recognize their cognate antigens with high specificity and, thus,
can be incorporated into the panel of antibodies used in IHC
experiments to distinguish the cell type that express proteins of
interest within heterogeneous clinical samples.
Protein Markers for Apocrine Breast Carcinoma
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FABP7 and HMGCS2 are highly expressed in benign
breast lesions with apocrine differentiation
Having ascertained the strict specificity of the antibodies
recognizing FABP7 and HMGCS2, we investigated their expres-
sion profiles by IHC on serial sections of lesions with various forms
of benign apocrine metaplasia. Thus, we evaluated the percentage
of positivity/negativity for HMGCS2 and FABP7 in 2 sets of
breast tissue samples, namely, non-malignant breast tissue
dissected from the areas adjacent to tumors (28 patients with
various types of breast tumors, Table S1) and 13 benign apocrine
microcysts obtained after surgery (Table S2). Expression of
cytoplasmic FABP7 and HMGCS2 as well as nuclear FABP7
was considered positive whenever we observed more than 60% of
cytoplasmic and above 1% of nuclear staining, respectively.
Representative IHC patterns are shown in Figure 2. FABP7
nuclear and cytoplasmic staining was not evaluated independently
because of limited number of samples presented in each group. As
seen, normal terminal ductal lobular units and normal ducts in
breast areas adjacent to tumor showed positivity for both proteins
neither in luminal cell nor in basal/myoepithelial cells (Figure 2A
and B and Figure 2E and F). However, areas with morphological
signs of apocrine differentiation exhibited sporadically positive
mosaic staining (Figure 2C and G, respectively). Most notably,
apocrine cysts exhibited a high immunoreactivity for both
HMGCS2 and FABP7 (Figure 2D and H, respectively). To
confirm these observations and to justify intracellular localization
of both proteins, we examined the expression pattern of HMGCS2
and FABP7 in apocrine cysts by double immunofluorescence
(Figure 3). As expected, normal mammary epithelial cells showed
little or no evidence of staining with either antibody (Figure 3, left
panel). On the contrary, lesions with apocrine metaplasia
(Figure 3, left panel) and apocrine cysts (right panel) were highly
Figure 1. 2D PAGE and 2D Western blot analysis of normal breast lesions and apocrine cyst. (A) 2D silver stained gel of protein lysate
from apocrine microcyst excised from tumor biopsy of patient 95 (GrI; ER+/PR+/AR+/HER21+). Positions of FABP7 and HMGCS2 identified by mass
spectrometry (MS) are indicated by blue arrows. Positions of apocrine differentiation, markers, 15-PGDH and ACSM1, described in our previous
studies are indicated by black arrows for reference. (B) 2D silver stained gel of protein lysate from distant normal (app. 3–4 cm from tumor mass)
breast lesion resected from mastectomy of patient 121 (GrII; ER+/PR+/AR+/HER22+). HMGCS2 and FABP7 have been identified by MS and are indicated
by blue arrows. Positions of HMGCS2, FABP7 (blue arrow) and 15-PGDH, and ACSM1 (black arrows) are indicated. The positions of HMGCS2 and
FABP7 on the 2D gel image (B) are located by matching of corresponding gel images by PDQUEST software. (C and D) 2D Western blot of protein
lysate from the same apocrine microcyst as in (A) developed either with anti HMGCS2 or anti FABP7 antibodies.
doi:10.1371/journal.pone.0112024.g001
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positive for both proteins. Taken together these experiments
showed a preferential expression of HMGCS2 and FABP7 in
benign breast lesions undergoing apocrine differentiation. Addi-
tionally, non-apocrine flat cysts (type II) that were detected within
analyzed lesions were completely negative for both HMGCS2 and
FABP7 in all cases (data not shown).
Based on the IHC scoring we have evaluated the percentage of
positivity/negativity of both proteins in apocrine cysts as
compared to non-apocrine lesions and shown that FABP7 was
positive in 12 out of the 13 apocrine cyst samples and negative in
22 out of the 28 non-apocrine samples (92,3% and 78,6%,
respectively; p,0.0001). Accordingly 10 out of the 13 apocrine
cyst samples (76,9%) and 26 out of 28 non-apocrine ones (92,8%),
were classified for HMGCS2 as positive and negative, respectively
(p,0.001). These results imply that FABP7 and HMGCS2 can be
considered as novel biomarkers for breast apocrine differentiation
that together with the apocrine biomarker panel reported by us in
previous studies, 15-PGDH+ HMG-CoA reductase+ and
ACSM1+ [2,16,19,28] may represent the golden standard for
defining the breast apocrine phenotype.
Expression of FABP7 and HMGCS2 by apocrine carcinoma
The baseline of expression for HMGCS2 and FABP7 in
apocrine carcinomas at the protein level was first evaluated in a
selected number of well differentiated IACs (6 samples) using 2D
PAGE and PDQUEST-based image analysis as compared to
TNBC (6 samples), Luminal B (7 samples) and HER2 (7 samples)
subtypes of which there was fresh frozen tissue. The representative
2D images of these breast cancer subtypes are shown in Figure 4.
All six of the analyzed IACs expressed both proteins (Figure 4A) as
it was determined by MS analysis and confirmed by 2D WB (data
not shown). No traces of these proteins were found in any of the 3
other breast cancer subtypes analyzed by 2D PAGE (Figure 4B, C
and D). Notably, the acidic isoform of HMGCS2 detected in IACs
is co-migrated with the basic variants of alpha-enolase (Figure 4A),
a protein that is highly expressed in all tumor subtypes analyzed
and, as a result, may mask the identification of HMGCS2 by 2D
PAGE in these samples. Hence, we performed IHC analysis of
these non-apocrine samples together with ADCIS and IAC and
confirmed that both proteins are expressed only by apocrine
carcinomas as exemplified in Figure 5. As seen, no positive
staining for HMGCS2 and FABP7 was observed in TNBC,
Luminal B and HER2 samples (Figure 5E–J). It is noteworthy,
that in both apocrine carcinoma types, ADCIS and IAC,
HMGCS2 displayed only cytoplasmic staining pattern (Figure 5B
and D). FABP7 also exhibited cytoplasmic intracellular localiza-
tion in both apocrine carcinomas, however, in invasive stages,
while retaining in cytoplasm, it was also detected in the nuclei with
positivity thresholds more than 1% (Figure 5C).
Based on these results we proceeded to test the putative two-
protein signature within the same unique Japanese collection of
apocrine carcinomas [21,29,30] that was used to validate the
previous protein signature [19]. In this large, well characterized
cohort, which is composed of 14 apocrine ductal carcinoma in situ
(ADCIS) and 33 IACs, more than 90% of the tumor cells exhibited
morphological features typical for apocrine cells [19,29]. All 14
ADCIS (100%) stained positively for HMGCS2 and 13 out of 14
(92%) were immunoreactive for FABP7 (Figure 6, Table S3) with
weak intensity of cytoplasmic staining (Table S3). As it was shown
previously, all samples did not express ER, PR, Bcl2 and GATA3,
but were positive for CD24 and AR (with one exception – ADCIS
12) [19]. The frequencies of HMGCS2 and FABP7 in 33 IACs as
evaluated by IHC are shown in Figure 6 and Table S4. HMGCS2
and FABP7 were positive in 100% (33/33) and 78% (25/32) of
IACs, respectively. Nuclear localization of FABP7 was associated
with invasive stage of apocrine carcinomas as it was detected in all
33 IAC samples but was not observed in any of the 14 ADCISs
(Table S3 and S4).
Figure 2. Immunohistochemical analysis of FABP7 and HMGCS2 expression in benign breast lesions with apocrine differentiation.
FFPE sections of normal breast and benign breast lesions with apocrine differentiation adjacent to tumor were stained with antibodies against FABP7
(upper panel) and HMGCS2 (low panel). (A) and (E) shows serial sections of normal breast tissue. Luminal and basal/myoepithelial cells are indicated
by red and black arrows, respectively. (B) and (F) show sections of large normal ducts. (C) and (G) show serial sections of breast lesions with benign
apocrine differentiation (apocrine adenosis). Positive and negative luminal cells are indicated by black and green arrows, respectively. (D) and (H)
show serial sections of lesions with apocrine cysts. Apocrine cysts with apical snouts and normal small ducts are indicated with black and green
arrows, respectively. Magnification: x10. Representative areas for each staining are shown in higher magnification (x20). The cut-off values for FABP7
and HMGCS2 are specified in Materials and Methods.
doi:10.1371/journal.pone.0112024.g002
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Expression of FABP7 and HMGCS2 by other breast
carcinoma subtypes
To determine whether FABP7 and HMGCS2 are exclusively
expressed by apocrine carcinoma we analyzed expression patterns
of these putative biomarkers in a set of 205 non-apocrine breast
tumors: 42 TNBC (21%), 103 Luminal A (50,2%), 17 Luminal B
(8,3%) and 43 HER2+ (20,5%) contained in three commercially
available tissue microarrays (BRC1501, 1502, and 1503; Pan-
tomics Inc.) (Figure 6, Table S5). The frequencies of positivity for
HMGCS2 and FABP7 as compared to IACs are summarized in
Figure 6B. In total, FABP7 positives were detected in 14 out of the
205 breast non-apocrine carcinomas (6,79%): 8 out of the 42
TNBCs (19,04%); 1 out of the 103 Luminal A subtypes (0,97%); in
none out of the 17 Luminal B (0%) and in 5 out of the 43 HER2+
(11,62%). HMGCS2 was expressed in 1 out of 42 TNBCs (2,38%);
18 out of 101 Luminal A (17,8%); 4 out of 17 Luminal B (23,5%)
and 11 out of 43 HER2+ (25,5%), in total: 34 out of the 203 non-
apocrine breast carcinomas (16,7%) (Figure 6B). The Fisher exact
test confirmed a statistical significant difference in frequencies of
HMGCS2 and FABP7 positives between IACs and Luminal A,
Luminal B, HER2+ and TNBC groups (p,0.0001 for both
proteins). No association was found between HMGCS2 expression
and ER or PR status, however, FABP7 is significantly more
positive among ER- and PR- breast cancers (p,0.0001).
Given that androgen receptor (AR) is widely expressed in
various breast cancer types [31] and leaning on our findings that
HMGCS2+/AR+/ER-/PR- phenotype is highly frequent in both
ADCIS and IAC subgroups (Figure 6A, Tables S3 and S4), we
calculated the frequency of this four-protein signature in non-
apocrine Pantomics dataset and revealed only 7 samples (3,5%)
with a combination of HMGCS2+/AR+/ER-/PR- (Table S5,
corresponding rows are highlighted by Thick Box Border). This
finding implies the contention that the HMGCS2+/AR+/ER-/
PR- profile is associated with breast apocrine malignancy
diagnosed by morphological criteria (p,0.0001) with a sensitivity
of 78,8% and a specificity of 96,6% (using a defined threshold).
Thus, HMGCS2+/AR+/ER-/PR- profile exhibited a significantly
higher sensitivity as compared with the AR+/ER-/PR- pheno-
type, which only provides a sensitivity of 54,17% for apocrine
tumors. Similar statistical evaluation performed for FABP7
demonstrated that FABP7+/AR+/ER-/PR- phenotype exhibited
75% of sensitivity and 94,7% of specificity, outperforming also the
steroidal profile alone.
Interestingly, among 7 non-apocrine samples showing
HMGCS2+/AR+/ER-/PR- profile 6 were HER2+ (86%;
remaining sample was classified as a borderline) (Table S5),
whereas in the entire cohort of 203 samples, HER2 positives were
observed in 58 samples (28,6%), indicating that among tumors
outside apocrine carcinoma the phenotype HMGCS2+/AR+/
ER-/PR- is correlated with HER2 amplification (p,0.003). The
high percentage of expression of HMGCS2 by HER2+ tumors
was further confirmed by IHC using an additional set of 16
samples of HER2+ lesions collected from the department of
pathology, Rigshospitalet, Copenhagen University Hospital (data
not shown).
Expression of apocrine differentiation markers in the
MDA-MB-453 cell line model for apocrine breast
carcinoma
The MDA-MB-453 breast cancer cell line obtained from a
malignant pleural effusion of a 48-year-old female is characterized
by AR+/ER-/PR-/HER2- profile is often used as a model to
study the molecular processes underlying apocrine breast malig-
nancy [32,33,34]. In view of this fact, we examined the expression
of FABP7 and HMGCS2 together with several other apocrine
protein markers in the MDA-MB-453 breast cancer cell line. IHC
analysis of MDA-MB-453 cells has been performed using a battery
of antibodies against FABP7, HMGCS2, 15-PHGDH, ACSM1
and GCDFP-15. Our data have shown that, in contrast to ADCIS
and IACs, MDA-MB-453 cells do not express either the FABP7 or
HMGCS2 (Figure S2). This cell line was also negative for 15-
PGDH and ACSM1 as well as for GCDFP-15 (Figure S2), which
is often considered as an apocrine marker protein in the breast.
The latter result is in agreement with the study by Vranic and co-
authors [35], who recently updated the molecular profile of the
Figure 3. FABP7 and HMGCS2 are colocalized in lesions with apocrine differentiation. Indirect double-label immunofluorescence analysis
of normal breast lesion with apocrine metaplasia (left panel) and apocrine cyst sections (right panel) reacted with FABP7 (subpanels B and F) and
HMGCS2 (subpanels C and G). Sections were counterstained with the nuclear stain DAPI (blue channel). Merge images are shown on subpanels (D)
and (H), respectively.
doi:10.1371/journal.pone.0112024.g003
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MDA-MB-453 cell line and concluded that these cells may not be
an ideal model of breast apocrine carcinomas. Consequently, our
data also support this output suggesting that, although the MDA-
MB-453 cells share certain features with apocrine breast carcino-
ma their metabolic phenotype remains plastic and may not
reproduce certain expression patterns and pathways which are
characteristic for apocrine differentiation in breast.
Evaluation of the transcriptomic molecular apocrine
signature at the protein level
Recently, a gene expression signature called ‘‘molecular
apocrine’’ has been proposed based on transcriptomic studies of
breast cancer tumors [12,14]. The molecular apocrine group is
AR positive but ER negative, with an increased androgen
signaling and some morphological features of apocrine tumors,
lacking, however, the strict criteria for diagnosis of classical
apocrine carcinomas. To our knowledge, the reliability and
significance of the apocrine breast carcinoma molecular signature
has not yet been systematically investigated at the protein level. In
order to find out to what extend the ‘‘molecular apocrine’’
signature correlates to the expression pattern of corresponding
proteins in various breast tumor subtypes we performed a detailed
IHC analysis of a 10-protein set selectively chosen from
transcriptomic apocrine signature. The selection of the candidate
genes was made on the following criteria: (i) their presence in the
signatures described by the molecular apocrine meta-analysis as
major top candidates [14] and (ii) the availability of specific
antibodies to the corresponding proteins suitable for immunohis-
Figure 4. 2D PAGE analysis of FABP7 and HMGCS2 expression among breast cancer subtypes. The representative images of IEF 2D PAGE
of protein lysates prepared from frozen sections of 4 breast tumor subtypes: IAC (A), TNBC (B), Luminal B (C) and Her2+(D). HMGCS2 and FABP7 have
been identified by MS and indicated by blue arrows. The positions of HMGCS2 and FABP7 on the 2D gels of TNBC, Luminal B and HER2 were
determined by matching of corresponding images by PDQUEST software. Alpha-enolase variants, identified by MS, are co-migrated with HMGCS2
and indicated by black arrows. Two other IAC markers, 15-PGDH and ACSMS1 described in our previous studies are shown for reference. IAC=
invasive apocrine carcinoma; TNBC= triple negative breast cancer. Tumors have been stratified as specified in Materials and Methods.
doi:10.1371/journal.pone.0112024.g004
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tochemical detection. Following these landmarks, we have chosen
10 genes consistently associated to the ‘‘molecular apocrine’’
signature: ABCA12 (ATP-binding cassette sub-family A member
12), BLVRA (Biliverdin reductase A), FOXA1 (Hepatocyte
nuclear factor 3-alpha), MLPH (Melanophilin), RHOB (Rho-
related GTP-binding protein RhoB), SIDT1 (SID1 transmem-
brane family member 1), SLC2A10 (Glucose transporter type 10),
SLC7A8 (L-type amino acid transporter 2), TSC22D3 (TSC22
domain family protein 3) and XBP1 (X-box-binding protein 1).
The expression pattern of selected candidates was tested by IHC
staining on paraffin sections prepared from selected pairs of benign
apocrine cyst and IAC, and representative IHC images are shown
in Figure 7. Very low immunoreactivity/negativity was observed
in both benign and malignant lesions for SCL2A10, SLC7A8 and
MPLH (Figure 7A and B; C and D, E and F, respectively), the
latter has a distinct apical expression pattern in apocrine cysts. The
other seven proteins displayed positive staining of various
intensities and localizations in both types of analyzed apocrine
lesions: FOXA1, XBP1, BVLRA and RHOB showed positive
cytoplasmic and nuclear staining in both cysts and IAC cells
(Figure 7G and H, I and J, K and L, M and N, respectively);
TSC22D3 was immunoreactive in nuclei of cysts and in nuclei/
cytoplasm of IAC cells (Figure 7O and P), whereas ABCA12 and
SIDT1 showed only cytoplasmic localization in both types of
lesions (Figure 7Q and R, S and T, respectively).
In order to identify whether or not these proteins are exclusively
expressed in breast lesions with apocrine differentiation including
IACs, we performed IHC analysis using tissue microarrays
(Pantomics Inc.) of non-IAC breast tumor subtypes which we
used in our previous experiments (see above). The results are
summarized in Figure 8 and demonstrate that the protein
expression of 8 genes from the transcriptomic signature, namely,
FOXA1, XBP1, BLVRA, ABCA12, SIDT1, RHOB, SLC2A10,
TSC22D3 is not apocrine-specific, because those proteins are
frequently expressed in other types of breast cancer (Figure 8).
Only 2 proteins, MLPH and SLC7A8, displayed low frequencies
of positivity in non-apocrine breast tumor subtypes (2,9% and
9,7% respectively; Figure 8). To estimate the value of MLPH and
SLC7A8 as putative markers for apocrine differentiation in breast,
we screened their expression in the sets of breast normal tissue (the
set is presented in Table S1), apocrine cysts (the set is presented in
Table S2) and independent set IACs (17 samples) collected from
the Department of Pathology, Rigshospitalet Copenhagen Uni-
versity Hospital. The representative IHC sections are shown in
Figure 9. All normal ducts and IACs were negative for MLPH.
However, 8 out of the 14 apocrine cysts (57%) showed positive
immunoreactivity for MLPH with a pattern restricted to the
membrane/cytoplasm of luminal cells in apical snouts (Figure 9B).
This pattern was also observed in sclerosing adenosis with
apocrine differentiation (Figure 9C). Interestingly, MLPH positive
expression was still retained by pseudo-glandular structures
present in one IAC sample (Figure 9D), suggesting that loss of
expression of MLPH protein in IACs may be due to a process of
dedifferentiation or loss of the glandular structure. As well, 87% of
non-malignant samples and 63% apocrine cysts displayed negative
staining with the antibody against SLC7A8. A very weak
cytoplasmic staining was observed in 30% of cysts. Notably, all
17 IAC samples were negative for SCL7A8. It is not inconceivable
that MLPH and SLC7A8 proteins are expressed and function in
apocrine carcinoma at a very low level but, consequently, all
oscillations in their expression are below the resolving power of the
IHC.
Discussion
The accurate diagnosis of breast apocrine carcinoma remains
controversial, mainly due to the rather subjective histopathological
criteria and the lack of sensitive and specific biomarkers, which
can reliably categorize this subtype of breast carcinoma. The
strategy we have employed to generate protein markers to
specifically categorize IAC and potentially be used as targets for
therapy, is based on the assumption that these lesions arise from
apocrine cells, which in turn are derived from normal breast
epithelial luminal cells that have undergone apocrine metaplasia
[1], i.e. transition from breast epithelial cells into an apocrine
sweat-gland type of cells [2,19,28]. Here we report an analysis of
Figure 5 Immunohistochemical expression analysis of FABP7
and HMGCS2 among breast cancer subtypes. The representative
IHC images of FFPE sections from 5 breast tumor subtypes immuno-
stained with antibodies against FABP7 (A,C,E,G and I) and HMGCS2
(B,D,F,H and J). ADCIS = apocrine ductal carcinoma in situ; IAC =
invasive apocrine carcinoma; TNBC= triple negative breast cancer.
Magnification: x10. Representative areas are shown in higher magnifi-
cation (x20) The cut-off values for FABP7 and HMGCS2 are specified in
Material and methods. Tumors have been stratified as specified in
Materials and Methods.
doi:10.1371/journal.pone.0112024.g005
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the expression of two novel putative protein biomarkers, FABP7
and HMGCS2, in breast lesions undergoing apocrine differenti-
ation: from benign apocrine metaplasia to invasive apocrine
carcinoma.
We have found that the lesions with apocrine metaplasia as well
as apocrine cysts in breast were highly positive for both HMGCS2
and FABP7 as compared to normal non-apocrine mammary
epithelial cells (p,0.001 and p,0.0001, respectively), implying
their value as novel biomarkers for breast apocrine differentiation.
HMGCS2 and FABP7 in combination with the panel published in
our previous studies, 15-PGDH+, HMGCR+ and ACSM1+
[2,16,19,28] may represent the golden standard for defining the
breast apocrine phenotype. Expression of FABP7 and HMGCS2
by invasive apocrine cancer was further demonstrated by IHC
using a well characterized set of apocrine carcinomas [2] in which
more than 90% of the tumor cells exhibited cytological features
typical of apocrine cells [21]. FABP7 positives were found in 78%
of all IAC cases and in 96% of ADCIS and only in 14 out of the
210 non-IAC breast tumor subtypes (6,6%). Tang and coauthors
[36] reported that FABP7 overexpression exhibited a strong
relationship with triple-negative cases (45,8%, p= 0.001) and the
basal-like subtype (37,5%, p= 0.001). Our results confirmed
partially a higher frequency of FABP7 positives in TNBC group
(,19%) as compared to the other subtypes of breast tumors
(Figure 6B). These findings are also in the line with the studies
showing that FABP7 is associated with the basal phenotype and
patient outcome in human breast cancer [37,38]. Importantly, our
data have demonstrated various sub-cellular localization of FABP7
in apocrine carcinomas and have shown that, unlike ADCIS, in
which FABP7 was detected mainly in the cytoplasm, in IACs
FABP7 was also observed in nuclei, which is in the line with recent
data demonstrating that nuclear location is associated with a more
aggressive phenotype of breast cancer [37,38]. It was also shown,
that FABP7 overexpression is correlated with pure glioblastoma
histology and that nuclear expression of FABP7 is more specifically
associated with more invasive tumors [39,40]. Taken together
these data support the contention that translocation of FABP7
between nuclei and cytoplasm may play a role in tumor
progression and further investigation should be undertaken to
understand roles of FABP7 signaling and intracellular traffic in
tumor biology.
To our knowledge, there are no data available on the expression
and activity on the protein level of HMGCS2, the gene that
controls the anabolic ketogenic pathway in breast cancer. Here we
have shown for the first time that HMGCS2 was up-regulated in
ADCIS and IAC and only rarely found in non-apocrine breast
carcinoma (Figure 6). Notably, HMGCS2 expression is retained
by all the IACs from our morphologically-defined cohort. This
stresses the potential value of HMGCS2 as a breast apocrine
cancer biomarker, since other apocrine differentiation markers
such as 15-PGDH, ACSM1 and HMGCR reported by us
previously, are expressed consistently in benign apocrine lesions
Figure 6. Expression profile of FABP7, HMGCS2 and other markers among breast cancer subtypes. (A) The diagram presents
immunohistochemical profiles of ADCIS, IACs and invasive ductal carcinomas (TNBC, Luminal A Luminal B and HER2) reacted with antibodies against
HMGCS2, FABP7, AR, ER, PR and HER2. The rows indicate the expression of particular protein in every core in breast cancer TMA (BRC1501, 1502 and
1503; Pantomics INC, USA): red box – positive staining, white box – negative staining, grey box – parameter was not determined. (B) Frequencies of
positives for HMGCS2 and FABP7 among breast cancer subtypes. ADCIS = apocrine ductal carcinoma in situ; IAC= apocrine carcinoma; IDC=
invasive ductal carcinoma; TNBC= triple negative breast cancer. The cut-off values for HMGCS2 and FABP7 are specified in Materials and Methods.
The cut-off values for ER, PR, AR and HER2 are specified in the Table S3 and S4.
doi:10.1371/journal.pone.0112024.g006
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but are conserved at lower frequencies or even negative in the
invasive stages [19]. Recently, Wang and co-authors using
Illumina expression array/RT PCR analysis sought to identify
risk biomarkers that are specific to ER status of breast cancer and
among several others revealed a significant overexpression of
HMGCS2 in ER- cases [41]. However, our data did not confirm
overexpression of HMGCS2 in ER negative tumors at the protein
level: the group of TNBCs displayed only ,2% positives for
HMGCS2 (Table S4).
IAC as defined by morphological criteria is often characterized
by a specific hormone receptor signature: AR+/ER-/PR-
[9,42,43,44,45] that has been proposed as a marker for
apocrine–type tumors by Tsutsumi and coauthors, who suggested
to include androgen receptor to immunohistochemical criteria
[46]. However, several studies reported a significant proportion of
AR+/ER-/PR- phenotypes outside breast apocrine malignancy:
59% in HER2+ type and 32% in basal-like tumors [31]; 39% in
ER- [47]; 10% in TNBC [10]. Our IHC data revealed only 22
AR+ER-PR- phenotypes out of the 205 non-apocrine samples
(10.7%) present almost exclusively in TNBC patients (6) and
HER2+ (14) samples. These discrepancies could be in part due to
the lack of consistent application of the morphological criteria and
the use of different methods and cut-offs values for positivity [9]
suggesting that hormonal status AR+/ER-/PR- may not be
sufficient to discriminate IAC from other breast cancer subtypes.
The results presented here demonstrate for the first time a very
high frequency of HMGCS2+/AR+/ER-/PR- phenotype (78,8%)
in IAC diagnosed by classical morphological criteria as compared
with the non-IAC control set (3%). We suggest that this four-
protein signature can categorize breast apocrine carcinoma more
Figure 7. Immunohistochemical analysis of molecular apocrine markers derived from trancriptomics data within the apocrine cyst
and carcinoma dataset. Representative staining of FFPE of apocrine cysts and IACs with antibodies against SLC2A10 (Glucose transporter type 10,
sections A and B) - cytoplasmic immunoreactivity; SLC7A8 (L-type amino acid transporter 2, sections C and D) - mainly cytoplasmic and membranous
immunereactivity; MLPH (Melanophilin, sections E and F) - cytoplasmic and luminal membranous immunoreactivity; FOXA1 (Hepatocyte nuclear
factor 3-alpha, sections G and H) – nuclear staining; XBP1 (X-box-binding protein 1, sections I and J) – mainly nuclear and cytoplasmic
immunereactivity; BLVRA (Biliverdin reductase A, sections K and L) - cytoplasmic immunoreactivity which combined with rare nuclear positivity; RHOB
(Rho-related GTP-binding protein RhoB, sections M and N) - cytoplasmic immunoreactivity; TSC22D3 (TSC22 domain family protein 3, sections O and
P) - mainly nuclear and cytoplasmic immunereactivity; ABCA12 (ATP-binding cassette sub-family A member 12, sections Q and R) - cytoplasmic
immunoreactivity and SIDT1 (SID1 transmembrane family member 1, sections I and G) - cytoplasmic immunoreactivity. Magnification: x10.
Representative areas are shown in higher magnification (x20) and examples of positive staining are indicated by red arrows.
doi:10.1371/journal.pone.0112024.g007
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confidently and supports the contention of a strict definition of
pure apocrine carcinomas as it was suggested previously [48].
The identification of differentially expressed proteins that
characterize the progression from early benign apocrine lesions
to invasive stages opens a window of opportunity for designing and
testing new approaches for pharmacological intervention as, for
example, 15-hydroxyprostaglandin dehydrogenase (15-PGDH)
and 3-hydroxymethylglutaryl-CoA reductase (HMGCR) are
currently being targeted for chemoprevention strategies in various
malignancies [49,50,51]. HMGCS2 is one of the rate-limiting
enzymes controlling generation and re-utilization of ketone bodies
[52]. Recently it was shown that ketone bodies support the driving
of neoplastic growth which is often accompanied by starvation of
all components of tumor environment and it has been speculated
that ketone inhibitors can be designed as novel therapeutics to
effectively treat advanced cancer patients [53,54]. Consequently,
HMGCS2, the enzymes associated with ketone body production
and re-utilization, might be considered as new ‘‘druggable’’ targets
Figure 8. Protein expression profile of transcriptome-derived apocrine markers among breast cancer subtypes. The diagram presents
immunohistochemical profiles of four breast tumor subtypes, TNBC, Luminal A Luminal B and HER2, reacted with antibodies against ten
transcriptome-derived apocrine markers: XBP1, TSC22D3, ABCA12, SIDT1, FOXA1, RHOB, BLVRA, SLC2A10, SLC7A8 and MLPH. The rows indicate the
expression of particular protein in every core in breast cancer TMA (BRC1501, 1502 and 1503; Pantomics INC, USA): red box – positive staining, white
box – negative staining grey box – parameter was not determined. Corresponding frequencies of positives are shown on the right side of the
diagram. Samples were considered as positive if 10% or more of the cells showed a clear positive staining with the antibodies. IDC= invasive ductal
carcinoma; TNBC= triple negative breast cancer. Tumors have been stratified as specified in Materials and Methods.
doi:10.1371/journal.pone.0112024.g008
Figure 9. MLPH is expressed by non-malignant apocrine cells but is lost in IACs. Representative images of FFPE sections immunostained
with antibody against MLPH. (A) normal ducts, (B) benign apocrine cysts (mainly luminal membranous immunoreactivity), (C) sclerosing adenosis with
apocrine differentiation, (D) IAC showing positive immunostaining in pseudo-glands structures (cytoplasmic and luminal membranous
immunoreactivity) and (E) IAC with negative immunostaining. Magnification: x20.
doi:10.1371/journal.pone.0112024.g009
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for anticancer therapy. Our finding that IACs are characterized by
an overexpression of HMGCS2, suggests that the patients
diagnosed with apocrine carcinoma might benefit from therapy
with HMGCS2 inhibitors. In addition, the high levels of AR
expression in the IACs makes this receptor a promising anticancer
therapeutic target for this type of breast cancer, but the ability to
exploit AR for therapy remains to be challenging [55,56,57,58].
Given that AR and HMGCS2 are both overexpressed in IAC, the
use of the dual therapy targeting two parallel AR and HMGCS2
pathways may provide an additional benefit for therapeutic attack
of breast apocrine carcinoma. HMGCS2 is the only gene from the
breast apocrine protein marker panel identified in our studies that
has been included in the molecular apocrine transcriptomic
signature [14], and was also found among the genes which
transcription was affected by modulation of AR/FOXA1 axis in
apocrine cells [59]. It is plausible, based on these findings, to
consider this enzyme as a "marker" to indicate an active AR,
which can be used to predict which tumors are driven by this
receptor and, therefore, capable of being treated with anti-
androgen therapy.
To date, there is uncertainty regarding the relationship between
molecular apocrine tumors identified by mRNA-array studies
[12,13,14] and histopatologically–diagnosed apocrine malignan-
cies. Thus, Lehman-Che and co-authors found only 4 tumors that
meet morphological criteria for apocrine tumors among 58
patients diagnosed as ‘‘molecular apocrine’’ [15], suggesting that
molecular apocrine subtype is much broader than initially
reported by Farmer and co-authors [12]. Apocrine transcriptomic
signatures contain several genes related to signaling pathways
(RHOB and SIDT1), transcription factors (FOXA1, XBP1,
TSC22D3) and transporters (ABCA12, SLC2A10 and SCL7A8)
that are not observed in our proteomic signature and therefore
were of interest to study. Our reciprocal IHC analysis of a set of 10
proteins selected from the major top candidates of molecular
apocrine signature: FOXA1, XBP1, BLVRA, ABCA12, SIDT1,
MLPH, RHOB, TSC22D3, SLC2A10 and SLC7A8 has revealed
only one protein, melanopholin (MLPH), an adapter protein
involved in melanosome transport to cell periphery [60], which
expression was specific for benign apocrine lesions, but was lost in
invasive stages. Most of other selected candidates were expressed
on protein level at different frequencies among non-IAC samples,
presumably because their function is related to housekeeping tasks.
The differences in concentration of mRNAs and proteins within a
cell is on average from 17 to over 50,000 copies, respectively [61],
and most studies agree that mRNA levels can explain only about
30–60% of protein abundance, so regulation of post-transcription,
translation and protein processing contribute as much to variation
in protein concentrations as transcription and transcript degrada-
tion do [62]. On the contrary, as we have seen for HMGCS2 and
FABP7, and previously for 15-PGDH, HMGCR, ACSM1 and
other proteins [2,16], the secondary metabolism of lipids, amino
acids and carbohydrates is strongly represented in apocrine cells,
providing a clear cut differentiation from other cell types of the
breast. Therefore, the unique metabolic identity of the apocrine
cells has offered so far the best candidates to identify IAC
biomarkers.
In conclusion, HMGCS2 and FABP7 are novel protein markers
for apocrine differentiation that are highly conserved among
apocrine breast tumors retaining their expression during tumor
progression. Inclusion of these markers into the protein signature
described previously: 15-PGDH, ACSM1 as well as markers that
are consistently expressed (AR, CD24) or not present (ER alpha,
PR, Bcl-2, and GATA-3) in benign apocrine lesions [19,28] may
categorize ADCISs and IACs with far more accuracy. Combina-
tion of HMGCS2 with steroidal profile (AR+/ER-/PR-) offers
greater sensitivity to detect breast apocrine tumors compared to
steroidal profile alone. Moreover, HMGCS2 widespread expres-
sion among IACs makes it a candidate to be studied as potential
therapeutic target for this malignancy. Integration of proteomic
and transcriptomic technologies applied to apocrine breast cancers
may offer complementary information about the particular biology
of this tumor subtype and the identification of biomarkers and
therapeutic targets of clinical importance.
Materials and Methods
Sample collection and handling
Tissue samples from 412 high risk breast cancer patients that
underwent breast surgery were obtained from the Department of
Pathology, Rigshospitalet, Copenhagen University Hospital be-
tween 2003 and 2014. The criteria for high risk cancer applied by
the Danish Cooperative Breast Cancer Group (www.dbcg.dk) are
age below 35 years old, and/or tumor diameter of more than
20 mm, and/or histological malignancy grade 2 or 3, and/or
negative estrogen and progesterone receptor status, and/or
positive axillary status. All patients did not receive preoperative
treatment. The samples were routinely collected within about 30–
45 min from the time of surgical excision. To evaluate the content
of tumor cells and the ration of tumor/stroma the hematoxylin/
eosin stained slides were prepared and reviewed by two researches
(IIG and M-L T). The age range was 32–84 with a mean average
of 59 years. All 412 samples collected during the above period
were subjected to 2D PAGE analysis. The samples were placed in
dry ice and were rapidly transported to the Danish Cancer Society
Research Center where they were stored at 280uC. Apocrine
carcinoma was morphologically defined as a carcinoma in which
more than 90% of the tumor cells showed typical apocrine
features. TNBC, Luminal B and HER2+ tumor subtypes were
defined in accordance with St. Galen classification [63]. The
project was approved (KF 01-069/03) by the Copenhagen and
Frederiksberg regional division of the Danish National Committee
on Biomedical Research Ethics. The written informed consent
from the donor was obtained for the use of the samples in research.
In addition, one set of specific samples comprising 14 ADCISs and
33 IACs diagnosed between 1997 and 2001 used in this study have
been described in previous publications [21,29]. Breast cancer
tissue microarray slides were obtained from Pantomics (BRC1501,
BRC1502 and BRC1503 Pantomics Inc., CA, USA). The TMAs
contain of 210 non overlapping breast tumors in total.
Antibodies
The polyclonal antibody raised against synthetic peptides of
human FABP7 (HPA028825), BLVRA (HPA042865), ABCA12
(HPA043194), SIDT1 (HPA035862), MLPH (HPA014685) were
purchased from Atlas Antibodies and were used in IHC at a
dilution of 1:200, 1:100, 1:500, 1:50 and 1:100 respectively in
accordance to the manufacturer instructions. The polyclonal
antibody against HMGCS2 (XW-7255) was obtained from BioSite
(Sweden) and was used in IHC at a dilution of 1:500. The
polyclonal antibody raised against synthetic peptides of human
FOXA1 (ab23738), XBP1 (ab37152) and RHOB (ab75064) were
purchased from Abcam and were used in IHC at a dilution of
1:400, 1:300 and 1:2000 respectively. The polyclonal antibody
against SLC2A10 (LS-B1622) and monoclonal antibodies against
TSC22D3 (LS-B4313) were purchased from LSBio and were used
in IHC at a dilution 1:2000 and 1:2000 respectively. The
polyclonal antibody raised against synthetic peptide of human
SLC7A8 (BMP041) was obtained from MBL and was used in IHC
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at a dilution 1:500. All dilutions were used according to the
manufacturer’s instruction. The antibodies against 15-PGDH,
ACSM1, GCDRP15, ER, PR, AR, HER2, 15-PGDH, ASCM1,
CD24, Bcl2 and GATA3 are described in our previous studies
[19,28].
2D PAGE and 2D Western immunoblotting
Twenty to thirty, 6 mm cryostat sections of frozen tissues were
resuspended in 0.1 ml lysis solution [64] or CLB1 buffer [65]. The
resulting lysates were frozen and kept at 220uC until used [66].
Twenty to forty ml were applied to the gels and each sample was
run at least in duplicate. The first and last sections of each sample
were used for IHC analysis using cytokeratin 19 (CK19) antibodies
to trace possible changes in epithelial cell pattern during tissue
sectioning. (CK19 is ubiquitously expressed by mammary epithe-
lial cells [67,68] and can serve as an additional control for the
sample quality. 2D PAGE (isoelectric focusing, IEF), silver staining
and 2D gel Western blotting were performed as previously
described [69].
Image analysis
For comparative proteomic analysis 2D gels were scanned and
analyzed using the PDQUEST software package from BioRad
(version 8.0.1). All detected proteins were identified by mass
spectrometry (see below), selected for the comparative analysis and
added to the master image.
Mass spectrometry analysis
Protein spots were excised from silver stained dry gels and the
gel pieces were re-hydrated in water. Gel pieces were detached
from the cellophane film and cut into 1 mm2 pieces followed by
‘‘in-gel’’ digestion as previously described [70] followed by a
procedure that has been reported previously [71]. Briefly,
MALDI-TOF-TOF data were acquired using an Ultraflex III
200 time-of-flight mass spectrometer (Bruker Daltonik, Germany)
equipped with a Smart beam laser and a LIFT-TOF/TOF unit.
Data acquisition and data processing were performed by the Flex
Control 3.0 and Flex Analysis 3.0 software (Bruker Daltonik,
Germany). All of the spectra were obtained using reflector positive
mode with an acceleration voltage of 25 kV, reflector voltage of
26.38 kV and detection suppressed up to 450 Da. A total of 2000
shots in steps of 200 shots were added to one spectrum in the mass
range of m/z 600–4000. Spectral analysis and protein identification
were performed as described previously. Protein identifications
were considered to be confident when the protein score of the hit
exceeded the threshold significance score of 65 (p,0.05) and no
less than 6 peptides were recognized.
Immunohistochemistry
The procedures for IHC have been described in detail in
previous publications [2,21,29]. For FABP7 and HMGCS2 we
used the following cut-off values: ADCIS: positive if 60% or more
of the CIS contained at least 30% of the cells reacting with the
antibodies. IACs: positive if 30% or more of the invasive cells
reacted with the antibodies. The cut-off values for ER, PR, AR,
HER2, 15-PGDH, ASCM1, CD24, Bcl2 and GATA3 are used as
described previously [19]. For XBP1, TSC22D3, ABCA12,
SIDT1, FOXA1, RHOB, BLVRA, SLC2A10, SLC7A8 and
MLPH we used the following cut-off values: positive if 10% or
more of the cells showed a clear positive staining with the
antibodies. TMAs were analysed by scoring of up to 5 separate
areas per single core and the intensities were averaged to generate
a summary score (percentage of cells stained, intensity). Frequency
distribution analyses were performed on GraphPad Prism 5
software (GraphPad Software, Inc, San Diego, CA, USA) using
Fisher’s exact test, considering a P value ,0.05 as statistically
significant. Immunohistochemical profiles were constructed using
Multiexperiment Viewer MeV [72].
Immunofluorescence on paraffin sections
Five-mm sections cut from paraffin blocks of breast tissue
samples were mounted on Super Frost Plus slides (Menzel-Gla¨ser,
Braunschweig, Germany), baked at 60uC for 60 min, deparaffi-
nized, and rehydrated through graded alcohol rinses. Heat
induced antigen retrieval was performed by immersing the slides
in Tris/EDTA pH 9.0 buffer (10 mM Tris, 1 mM EDTA) and
microwaving in a 750 W microwave oven for 8 min. Following
antigen retrieval sections were treated with Image-iT FX signal
enhancer (Molecular Probes, USA) to block non-specific staining
and subsequently incubated with the relevant primary antibodies
at appropriate dilutions. Detection of immune complexes was
done with species specific secondary antibodies conjugated to
Alexa Fluor 488 and Alexa Fluor 594 (Molecular Probes, OR,
USA). Nuclear material was counterstained with TO-PRO-3. The
sections were washed three times with cold phosphate-buffered
saline (PBS) between incubations. Normal rabbit or mouse serum
instead of primary antibody was used as a negative control.
Sections were imaged using a laser scanning microscope (Zeiss
LSM510Meta) as previously described [73].
IHC blocking with recombinant FABP7 and HMGCS2
The human recombinant FABP7 (H00002173) and HMGCS2
(H00003158) proteins were purchased from Abnova (USA). The
appropriate amount of corresponding antibodies (see above) were
diluted in TBS buffer to the final volume needed for staining of
two section slides and divided equally. The blocking recombinant
proteins FABP7 and HMGCS2 were added to a final concentra-
tion 5 mg/ml providing approximately 5-fold molar excess of
blocking peptide. Tubes containing either pure antibody or the
antibody mixed with corresponding recombinant protein were
incubated at room temperature for 1 hr with agitation. Two
identical tissue sections were probed with the blocked antibody
and antibody alone as described in the Immunohistochemistry
section.
Breast cancer cell lines
Human breast cancer cell line MDA-MB-453 was obtained
from the American Type Culture Collection (ATCC, Manassas,
VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco-BRL, Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS) at 37uC in a
humidifed CO2 incubator. The cell pellet from exponentially
growing breast cancer cells was collected by centrifugation at
1000 g to prepare the FFPE block. IHC staining was performed as
described above.
Supporting Information
Figure S1 Validation of anti-FABP7 antibodies specific-
ity towards highly homologous members of human fatty
acid-binding protein family. (A) 2D silver stained gel of
proteins extracted from tumor tissue obtained from TNBC patient
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22. (B) Zoomed fraction of area shown in (A) by dash rectangle.
Four members of FABP family, namely, FABP3, FABP4, FABP5
and FABP7 are indicated by red. Several other neighboring
proteins are indicated as references. The identity of all proteins
was determined by mass spectrometry analysis. (C) 2D Western
blot of 2D gel shown in (A). Only the fraction of blot image
corresponding to the area shown in (B) is presented. The
antibodies recognize only FABP7 but do not cross react with
FABP3, FABP4 and FABP5.
(TIF)
Figure S2 Immunohistochemical expression analysis of
FABP7 and HMGCS2 in MDA-MB-453 cell line. The FFPE
sections from breast cancer cell line MDA-MB-453 were
immunostained with antibodies against FABP7, HMGCS2, 15-
PGDH, ACSM1 and GCDFP-15. Magnification: x20.
(TIF)
Table S1 Expression of FABP7 and HMGCS2 in 28 normal
breast lesions adjacient to tumor.
(XLS)
Table S2 Expression of FABP7 and HMGCS2 in 13 breast
apocrine cysts.
(XLS)
Table S3 Expression of FABP7, HMGCS2 and several other
markers by 14 ADCISs.
(XLS)
Table S4 Expression of FABP7, HMGCS2 and several other
markers by 33 IACs.
(XLS)
Table S5 Expression of FABP7, HMGCS 2 and several other
markers in various nonapocrine breast tumors as determined by
IHC of TMA array (Pantomics 1501, 1502 and 1503).
(XLS)
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